Profile of gene expression regulated by induced p53: connection to the TGF-β family  by Kannan, Karuppiah et al.
Pro¢le of gene expression regulated by induced p53: connection to the
TGF-L family
Karuppiah Kannana, Ninette Amarigliob, Gideon Rechavib, David Givola;*
aDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel
bDepartment of Pediatric Hematology^Oncology, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University,
Tel Aviv, Israel
Received 19 January 2000; received in revised form 17 February 2000
Edited by Shmuel Shaltiel
Abstract The transcription regulatory function of p53 was
analyzed by using two inducible p53 systems in the human lung
cancer cell line H1299. cDNA probes derived from RNA
harvested 12 h after p53 induction were used to probe filters
containing cDNA arrays. Over 20 genes were found to be
significantly induced or suppressed by p53. The induced genes
can be classified mainly as cell cycle inhibitors like p21waf,
GADD45, apoptosis-related genes like Fas/APO1 and PIG3 or
DNA repair genes like DDB2, DNA ligase and G/T mismatch
DNA glycosylase. The suppressed genes include mainly cell cycle
regulators like cyclin B1, cyclin H and kinases like c-abl, CLK1
and others. The most notable induced gene was MIC-1, encoding
a TGF-L-related secretory protein, suggesting a potential
paracrine component for p53 growth suppression.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Normal cells respond to DNA damage and various stress
conditions (like oxidative stress, hypoxia or nucleotide deple-
tion) by activation and stabilization of p53 [1,2]. The activity
of p53 was found to be important for a variety of cellular
processes including growth arrest, apoptosis, senescence and
genome stability [3]. The most studied function of p53 in these
cell responses is its activity as a transcription factor which
regulates target genes whose products may be directly in-
volved in the biochemical regulation of these processes. The
DNA target site for p53 is composed of four palindromic
copies of the consensus sequence PuPuPuCA/T with a varia-
ble linker sequence in between [4] that was found to be located
in the promoter region or introns of such genes. Mutant p53
loses its ability to bind such target sites and therefore the
capacity to drive the cellular processes which are turned on
by wild-type (wt) p53. This loss-of-function of DNA target
recognition by p53 mutant is an important step in cell trans-
formation and over 50% of human cancers contain various
such p53 mutants [5]. This indicates that the transactivation
function of p53 is the basis of its function as a tumor sup-
pressor [6]. It follows that some of the genes that are trans-
activated by p53 can also be useful as inhibitor of tumor cell
growth and as candidates for new targets in cancer therapy. In
order to discover such genes, we used two systems of induced
p53 in a human lung cancer cell line: the muristerone-induced
human p53, described recently [7], and the temperature-sensi-
tive mouse p53Val135. The cDNA derived from mRNA har-
vested after p53 induction was hybridized to DNA arrays on
¢lters containing representatives of genes involved in cell
cycle, stress, apoptosis and cytokines (Clontech, USA). The
results revealed a pattern of p53-dependent gene expression
which includes genes related to cell cycle inhibition and DNA
damage repair (upregulated) and to positive regulators of cell
cycle genes like cyclins and kinases (downregulated). This
pattern included also some other genes associated with the
extracellular matrix and most notably a secretory protein
MIC-1 related to the TGF-L family. The results also demon-
strate the importance of transrepression by p53 (e.g. cyclin
B1) in the control of cell cycle checkpoint.
2. Materials and methods
2.1. Cell culture
The human lung cancer cell line H1299 was chosen for this study
since it is null for p53 [8]. Two di¡erent inducible p53 systems were
used in this work. One system consists of H1299 cells expressing the
mouse temperature-sensitive mutant p53Val135 (a gift of Dr. M.
Oren) which on temperature shift to 32‡C will assume wt conforma-
tion. The other system consists of muristerone inducible p53 (C-30)
and p21 (W-65) cell lines that were generated as described previously
[7,9]. The cells were maintained in RPMI medium containing 10%
fetal bovine serum (FBS). Both muristerone treatment (1 WM) and
temperature shift were carried out for a 12 h time period and then
the cells were harvested for RNA isolation.
2.2. RNA preparation
Total RNA was isolated using TRIZOL reagent (Gibco BRL, Life
Technologies, NY, USA). Cells were collected by centrifugation,
washed once with PBS, homogenized in 2 ml of TRIZOL reagent
per 100 mm cell culture plate and incubated for 5 min at room tem-
perature. Chloroform (400 Wl) was then added and the mixture was
vigorously mixed and incubated at room temperature for 3 min. After
centrifugation at 14 000 rpm, at 4‡C, for 20 min, the aqueous phase
was transferred into a fresh tube and equal volume of isopropanol
was added followed by incubation at room temperature for 10 min.
After centrifugation, the RNA pellet was washed once with 75%
ethanol and dissolved in DEPC water. The integrity of RNA was
checked on a 1% formaldehyde/agarose gel.
2.3. Northern blotting
For Northern blotting, 10 Wg of total RNA was denatured in form-
aldehyde bu¡er and run on a 1% agarose gel containing formalde-
hyde. The RNA was transferred onto Hybond N nylon membranes
(Amersham International Plc, UK) by capillary force overnight. The
transferred RNA was immobilized by baking at 80‡C for 2 h and UV
crosslinking. Hybridization was done at 65‡C for 12 h and washing
procedures were performed as in standard protocols. Autoradiogra-
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phy was done on Kodak X-ray ¢lms with intensifying screens at
370‡C.
2.4. cDNA array hybridization
We used cDNA arrays of human cDNAs spotted on a nylon mem-
brane (Atlas ¢lter arrays, Clontech, Palo Alto, CA, USA). We have
used a variety of Atlas arrays for human cDNAs including the human
stress/toxicology (234 genes), apoptosis (205 genes), cytokine/receptor
(268 genes) and human cancer 1.2 (1176 genes) arrays. The ¢lters
include also house keeping control cDNAs and negative controls
spotted in duplicate dots. A complete list of the cDNAs and controls
as well as their accession numbers is available on the web
(http://www.clontech.com/atlas/genelists/index.html). Total RNAs
were treated with DNaseI according to the manufacturer and used
for cDNA synthesis. A 3 Wl mix containing 5 Wg of total RNA and 1 Wl
of 10UCDS primer mix (speci¢c for each ¢lter array, provided by
manufacturer Clontech, USA) was incubated at 70‡C for 2 min fol-
lowed by incubation at 48‡C for 2 min. To this mix, 8 Wl of master
mix (containing 2 Wl 5Ureaction bu¡er, 1 Wl 10UdNTP mix, 3.5 Wl
[K-32P]dATP (3000 Ci/mmol, 10 mCi/ml, Amersham/Pharmacia Bio-
tech, UK), 0.5 Wl 100 mM DTT and 1 Wl MMLV reverse transcriptase
(50 U/Wl) were added, mixed and incubated for 25 min at 48‡C. The
reaction was terminated by adding 1 Wl of 10Utermination mix at
room temperature. The radioactively labeled cDNA mix was fraction-
ated on a Chroma Spin-200 column (Clontech Laboratories, USA)
and fractions that comprise the ¢rst peak of radioactivity were pooled
for each cDNA synthesis reaction. In each set of hybridization, equal
counts were taken for control and experimental labeled cDNA probes.
The labeled cDNA probe was then mixed with 1/10 volume of 10Ude-
naturing solution (1 M NaOH, 10 mM EDTA) and incubated at 68‡C
for 20 min followed by the addition of 5 Wl (1 Wg/Wl) of cot-1 DNA
and an equal volume of 2Uneutralizing solution (1 M NaH2PO4, pH
7.0), and incubated at 68‡C for 10 min. Denatured, labeled cDNA
was then added to 5 ml of ExpressHyb solution (Clontech) with 1 mg
of sheared salmon sperm DNA (Sigma, St. Louis, MO, USA) and
mixed. This hybridization solution was added to the Atlas cDNA
Expression Array membrane, which was prehybridized in 10 ml of
ExpressHyb hybridization solution at 68‡C for 1 h. Hybridization
proceeded overnight at 68‡C in a roller bottle. Membranes were
washed once with prewarmed 2USSC/1% sodium dodecyl sulfate
(SDS) for 30 min and once or twice with 0.5USSC/0.5% SDS for
30 min at 68‡C with constant agitation. The membranes were exposed
to Fuji X-ray ¢lms at 370‡C with intensifying screens.
2.5. Analysis of hybridization signals
The cDNA microarray autoradiograms were scanned and the im-
ages were analyzed using AtlasImage 1.01 software (Clontech, USA).
The background was calculated using default external background
calculation which takes into consideration the background signals at
blank space between the di¡erent panels of the arrays. Signal thresh-
old was set as background-based signal threshold. The signal inten-
sities were normalized globally using the sum method (AtlasImage,
Clontech, USA). A report of di¡erentially expressed genes was gen-
erated based on ratio and intensity di¡erences.
3. Results and discussion
3.1. Selection of cell lines and p53 induction conditions
The identi¢cation of p53 target genes required careful se-
lection of control cell lines. For example, the comparison of
the H1299Val135 RNA at 32‡C to that of H1299Val135 at
37‡C resulted in many changes in the expression of heat shock
genes and other genes related to the temperature of the
growth conditions which were not necessarily related to p53
induction. Hence, we compared H1299Val135 RNA at 32‡C
to that of H1299 at 32‡C. The comparison of RNA from
muristerone-induced p53 [7] to RNA from the same cell line
without muristerone also resulted in many di¡erences which
could be related to the possible e¡ect of muristerone. There-
fore, we chose to compare RNA from muristerone-induced
p53 in the C-30 cells to the RNA of muristerone-induced
p21waf in the W-65 cells [9]. This comparison should cancel
out the secondary e¡ect of growth arrest due to induced
p21waf in both cell lines, as well as a possible e¡ect of mur-
isterone on gene expression.
The time for harvesting the cells after p53 induction was
selected on the basis of monitoring the level of p21waf RNA
resulting from p53 induction by muristerone (Fig. 1). It is
shown that in C-30 cells, the p21waf, a typical p53-induced
gene, is fully expressed at 12 h after muristerone induction.
This time point was therefore chosen for extracting the RNA
from either H1299Val135 cells following the temperature shift
or from the muristerone-induced C-30 and W-65 cells.
3.2. p53-regulated genes in H1299 cell line
The results of hybridization to DNA arrays on two of the
¢lters provided by Clontech are shown in Figs. 2 and 3 and
some of the regulated genes are indicated by numbers; upre-
gulated genes are numbered in the upper panel and down-
regulated genes in the lower panel. It is shown that the in-
duced expression of p53 leads to both upregulation and
downregulation of genes. The upregulation of genes due to
transactivation by p53 was studied for many years and is de-
pendent on the presence of the target site sequence for p53
binding in the gene of interest [6]. On the other hand, the
downregulation of genes by p53, which may play an impor-
tant role in its function, is not fully understood with regard to
the mechanism of transcriptional repression by p53. Previous
work has shown that wt p53 binds the TATA binding protein
and reduces the e⁄ciency of transcriptional initiation, thereby
repressing gene expression [10]. This transcription inhibition
was e¡ective also on minimal promoters which lack p53 re-
sponse element, and it was argued that additional factors may
Fig. 1. Muristerone-induced mRNA of p53 and p21waf in C-30
cells. Northern blot analysis of RNA extracted from C-30 cells incu-
bated in the presence of 1 WM muristerone for the indicated time
periods.
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confer speci¢city on this inhibition. Recent analysis [11] sug-
gests that gene repression by p53 is also due to speci¢c bind-
ing of p53 to its target site and involved indirectly histone-
deacetylase (HDAC). HDAC was found to be involved in an
evolutionarily conserved mechanism of gene repression by
transcription factors [12]. It was shown that p53 is associated
with the corepressor mSin3A and HDAC at the promoter site
of the repressed gene, thus inducing chromatin condensation
and transcriptional repression which is dependent on p53 [11].
Another possibility to explain p53-induced repression was
based on the presence of a truncated target site, like a p53
half-site, resulting in repression rather than upregulation
[13,14]. In any event, the hybridization data and the list of
suppressed genes reported here make it clear that p53-induced
suppression is an important element of its activity.
3.3. Pattern and classi¢cation of gene expression after p53
induction
Table 1 provides the list of genes upregulated by p53 as
analyzed by screening the di¡erences in hybridization results
with the AtlasImage software. This list can be considered as a
pro¢le of the genes which may be directly related to the bio-
logical function of p53. Many of the induced genes were de-
scribed before (p21waf, MDM2, PIG3, GADD45, Fas, Bax,
PCNA) and they are related to the growth arrest and apop-
tosis function of p53 [6]. The e¡ect of p53 on genes involved
in DNA repair is markedly emphasized in our results. Genes
such as damage-speci¢c DNA binding protein 2 (DDB2), the
excision repair gene ERCC5, DNA ligase 1 (DNL1 or LIG1),
G/T mismatch speci¢c thymine DNA glycosylase (TDG) and
replication protein A1 (RPA1) are important genes activated
by p53 and are involved in DNA repair. An interesting new
p53 upregulated gene identi¢ed in this study is MIC-1, a
TGF-L like secretory protein. Fig. 4 shows the upregulation
of MIC-1 on a section from the Atlas 1.2 Cancer ¢lter (Clon-
tech, USA) and Fig. 5 shows a Northern blot which con¢rms
this result. This gene (also called PTGF-L) was recently iso-
lated as a novel macrophage inhibitory cytokine [15] or as a
prostate-derived di¡erentiation factor [16] and was shown to
induce cartillage formation. The promoter region of this gene
contains the putative p53 target site 5P-CATCTTGCCC/
AGACTTGTCT-3P, 851 bp upstream to the mRNA start
[17], and recent analysis demonstrated that this gene is regu-
lated by p53 and is also activated by etoposide in a p53-de-
pendent manner [18]. The MIC-1 (PTGF-L) product was
found to be secreted and the conditioned medium from cells
expressing this protein can suppress the growth of certain
tumor cells provided they contain TGF-L receptors and
Smad4 [18]. This indicates a connection between p53 and
the growth inhibitory family of TGF-L and implies a poten-
tially important paracrine mechanism for tumor growth sup-
pression by p53 [19].
In addition to the upregulated genes, we could observe a
high number of genes which are suppressed by induced p53
expression, suggesting that transrepression is also an impor-
tant mechanism through which p53 exerts its function. Down-
regulated genes are shown in Table 2. This list contains
mainly cyclins, NM23, topoisomerase IIK and replication fac-
tor C4 (RF-C4). In addition, Table 2 contains several kinases
Fig. 2. Di¡erential hybridization to stress/toxicology ¢lters. A:
RNA used for probes was derived from H1299Val135 incubated for
12 h at 32‡C. B: RNA used for probes was derived from H1299
cells incubated for 12 h at 32‡C. Numbers in A and B represent up-
regulated and downregulated genes, respectively. Upregulated:
1, p21waf; 2, PCNA; 3, DDB2; 4, LIG1; 5, MDM2; 6, Mortalin2.
Downregulated: 11, topoisomerase IIK ; 12, catechol O-methyltrans-
ferase.
Fig. 3. Di¡erential hybridization to apoptosis ¢lters. A: RNA used
for probes was derived from H1299Val135 cells incubated for 12 h
at 32‡C. B: RNA used for probes was derived from H1299 cells in-
cubated for 12 h at 32‡C. Numbers in A and B represent upregu-
lated and downregulated genes, respectively. Upregulated: 1, retino-
ic acid receptor L ; 2, Fas/APO1; 3, Bax; 4, BAK; 5, PIG3;
6, MDM2; 7, PCNA; 8, p57. Downregulated: 11, PDCD2; 12,
NIK; 13, E2F-5; 14, cyclin B1; 15, PLK1; 16, cyclin D1; 17,
cdc25c; 18, CLK1.
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including CDC like kinase 1 (CLK1) that activates protein
tyrosine phosphatase PTP-1B [20] ; NF-UB inducing kinase
(NIK) which is involved in the NF-UB inducing signaling
pathway [21] ; Polo/cdc5 like kinase (PLK) which is highly
expressed in various tumors and is required for cell division
[22]; CDC7-related kinase which may be involved in regula-
tion of G1/S transition and DNA replication [23]; rac-L ki-
nase (AKT2 oncogene) which is an oncogene ampli¢ed in
ovarian carcinoma and is activated by growth factors [24] ;
c-abl; NDR protein kinase which is a nuclear kinase impli-
cated in the regulation of cell division [25] ; protein tyrosine
kinase 9 (PTK9); Fas-activated serine^threonine (FAST) ki-
nase which is involved in signaling for Fas-mediated apoptosis
[26] and cyclin-dependent kinase 1 (cdc2 or CDK1) which is
involved in G1/S and G2/M transition [27]. All kinases men-
tioned here are directly or indirectly involved in cell division
and cell cycle control. Their suppression will lead to the sup-
pression of cell division which is consistent with the activity of
p53. Protooncogene c-abl was reported to increase the expres-
sion of p53 by neutralizing the e¡ect of MDM2 [28]. We have
observed transrepression of c-abl by overexpressed p53, sug-
gesting that this may represent a negative feed back loop
controlling the amount of p53 protein. Other notable genes
that were not reported earlier to be transrepressed by p53
include K-ras2, E2F-5 and NM23a and b. NM23 genes
(NDKs) were found to show reduced expression in tumors
progressing to the metastatic phenotype [29] and NM23b is
a transcriptional activator of c-myc [30]. By downregulating
NM23b, p53 may suppress one of the c-myc activating path-
way.
RF-C4 is required to assemble PCNA and DNA polymer-
ase N on the DNA template, and the resulting complex is
essential for the elongation of the primed DNA templates
during DNA replication [31]. By downregulating RF-C4,
p53 may inhibit DNA synthesis. On the other hand, LIG1
(upregulated gene in this study, Table 1) interacts with
FEN1 (Flap endonuclease 1) and inhibits DNA synthesis car-
ried out by DNA polymerase N/PCNA complex [32]. There-
fore, it seems likely that p53 function is executed by both
induction and suppression: inducing LIG1 that inhibits
DNA synthesis and suppressing RF-C4 that promotes it,
both ways leading to inhibition of DNA synthesis. The prop-
erty of DNA synthesis inhibition along with induction of
genes responsible for DNA repair may very well explain the
role of p53 as molecular guardian of the genome.
We also observe downregulation of cyclin B1, cyclin D1
Table 1
p53-induced genes in the H1299^Val135 system
Accession no. Gene/protein name Ratio Category
U09578a p21waf1 38.0 Cell cycle
AF010309 PIG3, p53-induced gene 3 11.0 Apoptosis
AF019770 MIC-1, member of TGF-L family 10.0 Growth inhibitor
Z12020a MDM2 8.3 Cell cycle
M15796a PCNA Cell Cycle
U18300a DDB2, involved in nucleotide excision repair 6.5 DNA repair
U70451a MYD88, myeloid di¡erentiation 5.4 Receptor
X07282 Retinoic acid receptor L 4.6 Development
M60974a GADD45 3.9 Cell cycle
Z70519 Fas/APO1 3.8 Apoptosis
L35253 MAPK14 3.8 Kinase
L22474 Bax, Bcl2-associated X protein 3.7 Apoptosis
M88279 FKBP4, possible peptidyl-prolyl-cis-trans-isomerase 3.1 Immunophillin
L15189a Mitochondrial stress 70 precursor (Mortalin2) 3.0 Cell cycle
U22398 p57KIP2, CDK inhibitor 1C 2.4 Cell cycle
M36067 LIG1, DNA ligase 1 2.3 DNA repair
L20046a ERCC5, DNA excision repair-related 1.9 DNA repair
U51166 TDG, G/T mismatch thymine DNA glycosylase 1.8 DNA repair
D11117a HOXD3, homeobox protein 1.8 Development
U77129 MAP4K5, activator of Jun N-terminal kinase 1.6 Kinase
M63488 RPA1, replication factor A protein 1 1.6 DNA repair
U23765 BAK1, Bcl2 antagonist/killer 1 1.5 Apoptosis
S81439a TIEG, TGF-L inducible early growth response gene 1.5 Cell cycle
L05624 MAP2K1, MEK1 1.5 Kinase
U16306a CSPG2, chondroitin sulfate proteoglycan 2 ECMb
Z21707a ZNF197, zinc ¢nger protein 197 (p18 protein) Unde¢ned
aThese genes are induced also in the muristerone inducible p53 system.
bECM = extracellular matrix.
Fig. 4. Di¡erential hybridization to MIC-1. A section of the ¢lm de-
veloped from cancer 1.2 array ¢lter is shown. A: RNA used for
probes was derived from H1299Val135 cells incubated for 12 h at
32‡C. B: RNA used for probes was derived from H1299 cells incu-
bated for 12 h at 32‡C.
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and cyclin H by induced p53 (Table 2). Cyclin H is a compo-
nent of CDK activating kinase [33], cyclin D1 (also known as
bcl-1 oncogene) is essential for G1/S transition and is overex-
pressed in many tumors [34]. Cyclin B1 is essential for G2/M
transition and it is well known that p53 is involved both in G1
and G2 arrest of the cell cycle [35]. It was proposed that there
may be two p53-dependent pathways that can contribute to
G2 arrest. One pathway was by decreasing the intracellular
levels of cyclin B1 [36]. The other pathway operates by in-
creasing the expression of 14-3-3c protein which prevents mi-
totic initiation by sequestering cdc25c [37], a phosphatase that
activates cdc2 by dephosphorylating it at tyrosine 15 [35]. Our
results show transrepression of genes involved in both these
pathways. A signi¢cant downregulation of cyclin B1 was ob-
served (Table 2). On the other hand, the downstream target of
14-3-3c, the cdc25c phosphatase, was downregulated, thus
bringing the expected decreased activation of cdc2. Both path-
ways converge on cdc2 kinase activity and we have observed
also downregulation of cdc2 kinase (Table 2). This indicates
that p53 acts in more than one place at the G2/M checkpoint
leading to G2 arrest. One should be cautious, however, in the
interpretation that all the regulated genes (listed in Tables 1
and 2) are primary targets of p53. This is because of the 12 h
time elapsed between p53 induction and harvesting the RNA.
This time point was chosen from RNA expression data (Fig.
1) and protein expression [7] aiming at maximal expression
using p21waf1 as an indicator for target gene induction.
Clearly the wt p53 is functional to variable degrees even be-
fore the 12 h time point. Hence, we cannot exclude the pos-
sibility that some of the genes listed here are not primary
targets of p53, but may be regulated by the products of the
primary targets of p53. It is however clear that many of the
genes (e.g. p21waf1, PIG3, MIC-1, MDM2, Bax, GADD45,
Fas/APO1 and cyclin B1) are known to contain the consensus
p53 binding site.
Several systems of p53 inducible genes were analyzed re-
cently at the level of genomic expression, using di¡erent ana-
lytical tools [19,38]. The results are not always similar, indi-
cating the heterogeneity of the p53 induction, depending on
cell lines and gene repertoire. Also in the genes listed in Tables
1 and 2, one could see the e¡ect of p53 on the expression of
many genes but not all of them are modulated similarly in the
two p53 inducible systems used in this analysis. This hetero-
geneity in the expression pattern could be explained by the
recent ¢ndings and suggestion that the p53-dependent gene
expression pattern may vary even between cell lines derived
Table 2
p53-suppressed genes in the H1299^Val135 system
Accession no. Gene/protein name Ratio Category
M25753 Cyclin B1 327.8 Cell cycle
X17620a NM23a, metastasis inhibition factor 314.0 Kinase
L16785a NM23b, transcriptional activator of c-myc 36.0 Kinase
L29222 CLK1, CDC like kinase 1 34.6 Kinase
M73791 Ribosomal protein L10 33.6 Protein synthesis
M96322a Kinase anchor protein (Gravin) 12 33.5 Sca¡old
Y10256 NIK, NF-UB inducing kinase 33.4 Kinase
U11791 Cyclin H 33.3 Cell cycle
U01038 PLK, Polo/cdc5 like kinase 33.0 Kinase
S78085a PDCD2, programmed cell death 2 gene 33.0 Apoptosis
M54968 p21 K-ras2 32.9 Cell cycle
U15642 E2F transcription factor 5 32.9 Cell cycle
M34065 CDC25C, tyrosine protein phosphatase 32.5 Cell cycle
M87339 RF-C4 32.4 Cell cycle
AF015592 CDC7-related kinase 32.3 Kinase
M33294 TNF receptor 1A 32.3 Apoptosis
M77198 AKT2 oncogene, rac-L kinase 32.3 Kinase
U77845 TRIP, TRAF interacting protein 32.2 Apoptosis
X59798 Cyclin D1 32.2 Cell cycle
J04088a Topoisomerase (DNA) IIK 32.1 DNA repair
M14752 c-abl protooncogene, tyrosine protein kinase 32.0 Kinase
Z35102a NDR protein kinase 32.0 Kinase
U02680 Protein tyrosine kinase 9 31.9 Kinase
X86779 Fas-activated serine^threonine (FAST) kinase 31.9 Kinase
X05360 Cyclin-dependent kinase 1 31.8 Kinase
aThese genes are suppressed also in the muristerone inducible p53 system.
Fig. 5. Northern blot analysis of three typical induced genes,
p21waf, Fas and MIC-1. RNA derived from H1299Val135 cells and
H1299 cells after 12 h incubation at 32‡C was separated on a 1%
agarose gel and blotted onto nylon ¢lters. The blot was hybridized
to probes of p21waf, Fas and MIC-1.
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from the same clone and depends also on the nature of p53
induction signal and on the cell type [38]. In conclusion, the
p53-dependent gene expression pro¢le showed upregulation of
cell cycle inhibitor and of DNA repair genes and downregu-
lation of cyclins and kinases that promote cell cycle and cell
division. The overall pattern appears to be in line with the
proposed growth suppressive function and DNA repair activ-
ity of p53. In addition, some novel genes, the expression of
which is modulated by p53 (e.g. MIC-1, cyclin B1 and others),
were listed which may open up new avenues for future re-
search on growth control.
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